A retrospective, case-control study of efficacy and safety of Anlotinib in the second-line or further for the treatment of lung cancer
Latest Information Update: 25 Jul 2021
At a glance
- Drugs Catequentinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology